The effect of entacapone on homocysteine levels in Parkinson disease

Neurology

Volumn 64, Issue 8, 2005, Pages 1482-

  Ostrem, J L ^a,b,c   Kang, G A ^b,c,d   Subramanian, I ^b,c,d   Guarnieri, M ^e   Hubble, J ^e   Rabinowicz, A L ^e   Bronstein, J ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENTACAPONE; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 17644411467     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000158674.91134.6E     Document Type: Article

References (6)

1. Postume R, Lang A. Homocysteine and levodopa. Should Parkinson disease patients receive preventive therapy? Neurology 2004;63:886-891.
2. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55-66.
3. Koller W, Guarnieri M, Bubble J, Rabinowicz AL, DS, Group atS-T. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005;112:221-230. Epub 2004 Oct 22.
4. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2004 (early view).
5. Guttormsen AB, Solheim E, Refsum H. Variation in plasma cystathionine and its relation to changes in plasma concentrations of homocysteine and methionine in healthy subjects during a 24-h observation period. Am J Clin Nutr 2004;79:76-79.
6. O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004 (early view).